Trial Information
Clinical Registry Describing Treatment Reality and Therapy Modality of Patients With Metastatic or Locally Advanced Renal Cell Carcinoma Requiring Therapy
Inclusion Criteria:
- Patients with metastatic or locally advanced Renal Cell Carcinoma requiring therapy
- Start of first palliative therapy within 1 year before enrollment of patient to
registry; since enrollment of 1000 Patients: start of first palliative therapy within
4 weeks before enrollment
Exclusion Criteria:
-
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Documentation of therapies
Outcome Time Frame:
9 years, 3 years per patient
Safety Issue:
No
Authority:
Germany: Ethics Commission
Study ID:
IOM RCC
NCT ID:
NCT00610012
Start Date:
December 2007
Completion Date:
Related Keywords:
- Renal Cell Carcinoma
- Advanced Renal Cell Carcinoma
- MRCC
- Therapy-reality
- Observation
- Registry
- RCC
- ARCC
- Germany
- Metastatic Renal Cell Carcinoma
- Renal Cell Carcinoma
- Renal Cell Cancer
- Sorafenib
- Sunitinib
- Interferon
- Interleukin
- Temsirolimus
- Pazopanib
- Cytokines
- VEGF
- Carcinoma
- Carcinoma, Renal Cell